Navigation Links
Queen Latifah's 'Trav'lin Light' Tour to Be Sponsored by Jenny Craig
Date:10/10/2007

-Queen Latifah to deliver healthy lifestyle message-

CARLSBAD, Calif., Oct. 10 /PRNewswire/ -- Jenny Craig Inc. today announced that it is a co-sponsor of Queen Latifah's 2007 Trav'lin Light tour. Queen Latifah and Jenny Craig will use the sponsorship to increase awareness about the health risks associated with obesity (e.g., diabetes) and to promote Jenny Craig's "Healthy Curves are Beautiful Curves(TM)" campaign. Queen Latifah is not currently participating in the Jenny Craig Weight Loss Program, but she believes it is one of a range of ways people can reduce their weight and thereby enhance their health.

Jenny Craig's CEO, Patti Larchet said "Queen Latifah is a tremendous performer with broad appeal that spans genders and races. She's also a powerful role model for women's self-reliance and self-esteem. We are proud to help bring her talent to America."

Queen Latifah personally understands the severity of obesity-related illnesses -- having lost her great-grandmother to diabetes. Diabetes is named by the World Health Organization as "the global health hazard of the 21st Century" and is often a direct result of weight gain. She said "Jenny Craig's sponsorship of my tour will allow me to begin a dialogue with my fans about healthful living. My hope is to educate people on the simple nutritional steps they can take to have a positive impact on the length and quality of their lives.

"Do you know," Queen Latifah added, "that by losing just 5%-7% of their body weight, an overweight person can lower their risk of developing Type II diabetes by 58%?"

According to the American Diabetes Association, "nearly nine out of ten people with newly diagnosed Type II diabetes are overweight and losing that weight could better manage their diabetes."

The Trav'lin Light tour will take place between September 29 and November 20th. Queen Latifah will travel across the United States, making dozens of stops at intimate venues. She will
'/>"/>

SOURCE Jenny Craig Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Beauty Queens Urge On The Importance Of Maintaining Bone Integrity
2. Queensland Bans OTC Sales Of Cold And Flu Drugs
3. Queensland Opposition not happy over hiring consultancy
4. The mystery of the bulge in North Queenslanders
5. Queensland : Call for improved mental health services
6. Surgery cancellations in Queens land Hospital
7. Mammograms in Queensland Reviewed
8. Queensland Government to Meet its Medical Targets
9. Meningococcal Scare in Queensland
10. Medical Person As Health Minister To Improve Queenslands Health System
11. Dentist Tested Positive For HIV - Queensland Health To Screen Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ting firm LocumTenens.com, a leading provider of t...e its agreement with VHA Inc., a national healthca... assignments. , Alpharett...uiting firm LocumTenens.com , a leading provider...nounce its agreement with VHA Inc., a national hea...
(Date:11/24/2009)...use of inflammatory bowel disease is largely unkno... 2009 Advances in Inflammatory Bowel Diseases, the...inical & Research Conference, December 3-6 in ...mutation for Crohn’s disease. , ...9 -- The molecular cause of inflammatory bowel dis...
(Date:11/24/2009)...SNewswire/--GovernorEdwardG.Rendelltodayannouncedt...ccinatedduringtheweekendatpublichealthclinicsheldb..., "Withthefederalgovernmentunabletoprovideaccur...ofH1N1vaccine,distributionhasbeenchallenging,"said...ccinedistributionprocessinPennsylvania.Holdingpubl...
(Date:11/24/2009)...e/--AgitoNetworks,Inc.,thecompanydeliveringinnovat...titwashonoredintheEverythingChannelTechInnovatorAw....0.EverythingChannel,sTechInnovatorAwardscelebrate...tdriveadvancesthroughoutthetechnologychannel. ,...pplicationsforthe2009EverythingChannelTechInnovato...
(Date:11/24/2009)...wire/--Nextmonth,UnitedHealthcarewilloffertwofreeM...ricanseniorsunderstandthebasicsofMedicare.Followin...174;Goldclass,aLatin-infusedfitnessprogramthatblen.... ,, UnitedHealthcarewilloffertheseseminarsinSp...arningabouttheirhealthcareoptions. Thereareapprox...
Breaking Medicine News(10 mins):Health News:VHA Names LocumTenens.com as Preferred Physician Staffing Vendor 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 4Health News:Governor Rendell Announces 100,000 At-Risk Pennsylvanians Vaccinated at H1N1 Public Health Clinics; Addresses Future Vaccine Distribution Plans 2Health News:Agito Networks Recognized in the 2009 Tech Innovators Awards Program by Everything Channel 2Health News:Agito Networks Recognized in the 2009 Tech Innovators Awards Program by Everything Channel 3Health News:UnitedHealthcare To Offer Seniors Hispanic-Centered Medicare Education Seminars Combined With a Latin-Themed Fitness Program 2
...leep Loss Costs Economy up to $15 Billion Each Yea...S, March 30 Now more than ever, Americans need th...of the first things people scrimp on when time is ...p in America poll by the National Sleep Foundation...
...nhancements maximize and automate physician practi...ain financial edge during economic downturn , , ...ding developer of healthcare software solutions fo...ca,s award-winning Electronic Health Record (EHR) ...
... , , , - Lorcaserin Very Well Tolerated Througho... for Today at 8:30 a.m. EDT , , SAN DIEGO, March...ARNA ) announced today positive top-line results f...ficacy of lorcaserin for weight management. Statis...
...INCINNATI, March 30 LCA-Vision Inc. (Nasdaq: LC...n services under the Lasik Plus (R) brand, today a...g with the Securities and Exchange Commission, the... Additionally, the Joffe Group stated that it has...
...ompany also Introduces Everest Award for Hospitals... , ANN ARBOR, Mich., March 30 The Healthcare bus... study identifying the 100 top U.S. hospitals base...Hospitals National Balanced Scorecard that evaluat...
...orld-renowned neurosurgeon for over 40 years, Dr. ...body and spirit are essential for optimum health. ...Ft. Wayne, Indiana, Rudy Kachmann, M.D., creator o...s. Now, having retained award-winning TransMedia G...
Other Medicine News:Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 2Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 3Health News:iMedica Corporation Announces the Release of Patient Relationship Manager 2009 2Health News:iMedica Corporation Announces the Release of Patient Relationship Manager 2009 3Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 2Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 3Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 4Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 5Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 6Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 7Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 8Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 9Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 10Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 11Health News:LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees 2Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 2Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 3Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 4Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 5Health News:Dr. Rudy Kachmann, Neurosurgeon, Author, Lecturer & Founder of Kachmann Mind Body Institute Selects TransMedia Group as Agency of Record 2
(Date:11/24/2009)...ov.24/PRNewswire/--ZargisMedicalCorp.,asubsidiaryo...sCorporateResearch(NYSE: SI ),todayannouncedthatit...2009episodeofCBS, TheEarlyShow duringasegmentinwhi...eviewedfivewinningproductsfromthepublication,s2009...dely-viewedtelevisionmorningnewstalkshowbroadcastb...
(Date:11/24/2009)...PRNewswire/--AmbitBiosciencesCorporationannouncedt...AC220,anovelsecondgenerationFLT3inhibitor,inAMLatt...)tobeheldinNewOrleans,LA,December5-8,2009.Anoralpr...lPhaseImonotherapysafetystudyinadultswithacutemyel...bepresentedevaluatingtheeffectofAC220monotherapyan...
(Date:11/24/2009)...ov.24/PRNewswire-FirstCall/--EchoTherapeutics,Inc....e-freeSymphony(TM)tCGMSystemasanon-invasive,wirele...temanditsPrelude(TM)SkinPrepSystemfortransdermaldr...ChairmanandChiefExecutiveOfficer,willpresentatthe1...nce,sponsoredbytheNewYorkSocietyofSecuritiesAnalys...
Breaking Medicine Technology:Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 3Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference 2Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 14655 1Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 14655 2Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 14655 3YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 1YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 2YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 3YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 4Beckman Coulter Announces Third Quarter 2009 Results 5858 1Beckman Coulter Announces Third Quarter 2009 Results 5858 2Beckman Coulter Announces Third Quarter 2009 Results 5858 3Beckman Coulter Announces Third Quarter 2009 Results 5858 4Beckman Coulter Announces Third Quarter 2009 Results 5858 5Beckman Coulter Announces Third Quarter 2009 Results 5858 6Beckman Coulter Announces Third Quarter 2009 Results 5858 7Beckman Coulter Announces Third Quarter 2009 Results 5858 8Beckman Coulter Announces Third Quarter 2009 Results 5858 9Beckman Coulter Announces Third Quarter 2009 Results 5858 10Beckman Coulter Announces Third Quarter 2009 Results 5858 11Beckman Coulter Announces Third Quarter 2009 Results 5858 12Beckman Coulter Announces Third Quarter 2009 Results 5858 13Beckman Coulter Announces Third Quarter 2009 Results 5858 14Beckman Coulter Announces Third Quarter 2009 Results 5858 15Beckman Coulter Announces Third Quarter 2009 Results 5858 16Beckman Coulter Announces Third Quarter 2009 Results 5858 17Beckman Coulter Announces Third Quarter 2009 Results 5858 18Beckman Coulter Announces Third Quarter 2009 Results 5858 19Beckman Coulter Announces Third Quarter 2009 Results 5858 20Beckman Coulter Announces Third Quarter 2009 Results 5858 21Beckman Coulter Announces Third Quarter 2009 Results 5858 22Beckman Coulter Announces Third Quarter 2009 Results 5858 23Beckman Coulter Announces Third Quarter 2009 Results 5858 24Beckman Coulter Announces Third Quarter 2009 Results 5858 25Beckman Coulter Announces Third Quarter 2009 Results 5858 26Beckman Coulter Announces Third Quarter 2009 Results 5858 27Beckman Coulter Announces Third Quarter 2009 Results 5858 28Beckman Coulter Announces Third Quarter 2009 Results 5858 29Beckman Coulter Announces Third Quarter 2009 Results 5858 30Beckman Coulter Announces Third Quarter 2009 Results 5858 31Beckman Coulter Announces Third Quarter 2009 Results 5858 32Beckman Coulter Announces Third Quarter 2009 Results 5858 33Beckman Coulter Announces Third Quarter 2009 Results 5858 34Beckman Coulter Announces Third Quarter 2009 Results 5858 35
...oBio Corporation is,presenting safety and efficacy...alis (cold sores) and onychomycosis (toe nail fung...of Dermatology (AAD), being held February,1-5, 200...cate that the company,s topical lotions,composed o...and antifungal,effects without safety concerns or ...
...ts targeted as part of innovative,Therapeutics Dev...f its ongoing,efforts to do whatever it takes to s...ure for Parkinson,s disease, The Michael J. Fox,Fo...o $3 million in total,funding to four industry tea...ser to the clinic. The awards were granted under M...
Other Medicine Technology:NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008 2NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008 3Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 2Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 3
...eoGen surgically implanted bone growth stimulator ... when surgery is already planned or when patient c...s totally surgically implanted, patients are assur...on site 24 hours a day for up to 6 months. , ,...
BIG ADVANTAGE Cannulated Titanium Interference Screws
...rew ACL Interference Screw is indicated for graft ...and PCL reconstructions with bone-patellar tendon-... SmartScrew ACL provides easy and atraumatic inser... type. The unique Self-Reinforced 96L/4D copolymer...
ADVANTAGE Titanium Cannulated Interference Screws
Medicine Products: